|
시장보고서
상품코드
1618285
세계의 이동식 심장 모니터링 디바이스 시장 평가 : 디바이스 유형별, 최종사용자별, 지역별, 기회, 예측(2018-2032년)Ambulatory Cardiac Monitoring Devices Market Assessment, By Device Type, By End-user, By Region, Opportunities and Forecast, 2018-2032F |
||||||
세계의 이동식 심장 모니터링 디바이스 시장 규모는 2023년 69억 7,000만 달러에서 2032년에 148억 달러에 달할 것으로 예측되며, 예측 기간인 2025-2032년에 CAGR로 9.88%의 성장이 전망됩니다. 시장 성장을 지원하는 다양한 요인으로는 사람들의 심장 건강에 대한 인식 증가, 적절한 모니터링 장비가 필요한 심장질환의 이환율 증가, 기술 발전, 의료 인프라 및 서비스에 대한 투자 증가 등이 있습니다. 또한 외래 환자 동향과 원격의료 서비스 증가는 원격 모니터링 기술의 성장을 가속하고 있습니다.
이동형 심장 모니터는 환자의 심장 활동을 장기간에 걸쳐 기록합니다. 이러한 툴은 일상적인 임상 심전도 검사로는 확인할 수 없는 심장질환을 진단하고 관리하는 데 매우 중요합니다. 전 세계에서 심혈관 질환이 급증함에 따라 모니터링 장비의 사용이 필요하게 되었습니다. 미국심장학회(American College of Cardiology)에 따르면 CVD로 인한 전 세계 사망자 수는 1990년 약 1,240만 명에서 2022년 1,980만 명으로 증가할 것으로 예상하고 있습니다. 증가할 것으로 예상됩니다. 질병 유병률 증가와 건강한 라이프스타일에 대한 인식을 높이기 위한 정부의 구상은 세계 이동식 심장 모니터링 디바이스 시장을 주도하고 있습니다.
다국적 기업은 심장 모니터링 제품을 강화하기 위해 전략적 인수를 통해 이동식 심장 모니터링 디바이스 시장의 성장을 가속하고 있으며, 2024년5월WearLinq, Inc.는 AMI Cardiac Monitoring, LLC를 인수했습니다. 이 인수와 최근 670만 달러의 자금 조달을 통해 WearLinq는 고급 eWave 6 리드 ECG 모니터에 대한 접근성을 높일 수 있게 되었습니다. 또한 실시간 데이터 전송 및 원격 환자 관리로 인해 원격의료는 이동식 심장 모니터링 디바이스 시장을 주도하고 있습니다. 이러한 통합을 통해 환자 참여도를 높이고 의료진이 보다 적절하고 시기적절한 의사결정을 내릴 수 있도록 돕습니다. 시간이 지남에 따라 이러한 장비는 점점 더 많이 사용 가능해져 심혈관 치료와 환자 결과를 개선할 수 있는 유익한 기회를 제공하게 될 것입니다.
세계의 이동식 심장 모니터링 디바이스 시장에 대해 조사분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업의 상황 등을 제공하고 있습니다.
Global ambulatory cardiac monitoring devices market is projected to witness a CAGR of 9.88% during the forecast period 2025-2032, growing from USD 6.97 billion in 2023 to USD 14.80 billion in 2032. Various factors supporting the market growth include rising awareness of cardiac health among individuals, increasing incidences of heart diseases, which demand suitable monitoring devices, technological advancements, and growing investments in healthcare infrastructure and services. Additionally, the outpatient trend and increased telehealth services promote the growth of remote monitoring technologies.
Ambulatory cardiac monitors record heart activity in a patient over a long period. These tools are crucial in diagnosing and managing cardiac conditions that would otherwise not be identified using routine clinical ECGs. The surge in cardiovascular diseases globally has necessitated the use of monitoring equipment. Lifestyle factors include diet, lack of physical activity, smoking, and exposure to air pollution, which have significantly contributed to this trend. According to the American College of Cardiology, the global deaths due to CVD have increased from around 12.4 million in 1990 to 19.8 million in 2022. The increasing prevalence of diseases and efforts from the government to raise awareness towards healthy lifestyles drive the global ambulatory cardiac monitoring devices market.
Multinational companies are making strategic acquisitions to enhance their cardiac monitoring products, driving growth in the ambulatory cardiac monitoring devices market. In May 2024, WearLinq, Inc. acquired AMI Cardiac Monitoring, LLC. This acquisition, combined with a recent funding round of USD 6.7 million, allows WearLinq to increase access to its advanced eWave 6-lead ECG monitor. Moreover, telehealth is also driving the market for ambulatory cardiac monitoring devices due to real-time data transmission and remote patient management. This integration boosts patient engagement and allows healthcare providers to make better, more timely decisions. With time, such devices will become increasingly available, offering fruitful opportunities for improved cardiovascular care and patient outcomes.
Growing Awareness About Cardiac Health Boosts Market Demand
Growing heart health awareness has led to a high demand for ambulatory cardiac monitoring devices. With greater public awareness of CVDs, people are becoming more proactive in seeking preventive measures and monitoring solutions. Also, organizations have increased efforts to educate the public about heart health, risk factors, and the significance of regular monitoring. All these have done much more to raise the visibility and demand for cardiac monitoring devices. On World Heart Day in September 2024, P. D. Hinduja Hospital and Medical Research Centre launched the campaign "Unmute Your Heart." This campaign highlighted the urgent need to prioritize heart health by adopting healthy lifestyle changes.
Similarly, in October 2024, Emcure Pharmaceuticals Ltd. launched a campaign called "ACE YOUR HEART," an awareness focus on cardiovascular health in India. In this campaign, they collaborated with more than 5,000 doctors nationwide to raise awareness about heart health. The company created the record-breaking largest heart structure to show its continued commitment to heart health. Such growing initiatives by organizations support market growth. As awareness of heart health increases, it is an ideal environment for the ambulatory cardiac monitoring devices market, offering scopes for innovation and greater adoption by consumers and healthcare providers alike.
Recent Advancements in Wearable Devices are Supporting Market Growth
The newest advances in ambulatory cardiac monitoring equipment are revolutionizing the scope of cardiac monitoring because they obtain and analyze long-term cardiac information to give a more precise diagnosis. Such advancements have made ambulatory monitoring devices popular for continuous heart monitoring, providing an affordable yet efficient way to monitor vulnerable patients from their homes. The integration and advancements in signal processing bring better accuracy and accessibility. They help in the early detection of critical physiological changes for timely medical alerts. Advances in wearable technology have made patients' health data more accessible, thus promoting proactive care for cardiovascular diseases. The more healthcare becomes aligned with wearables, the more its adoption rates should also rise. Changes like this can only lead to better patient outcomes and address the growing demand for effective cardiac monitoring solutions.
Companies also invest in digital healthcare and remote patient monitoring technologies that complement ambulatory cardiac devices. In May 2024, VivaLNK, Inc. launched a complete Mobile Cardiac Telemetry (MCT) and Holter monitoring solution that integrates remote patient monitoring (RPM) technology with advanced arrhythmia detection. This approach improves patient care, simplifies deployment, and decreases costs through unified MCT and Holter monitoring technology.
ECG Devices Segment Dominates the Market
ECG devices dominate the ambulatory cardiac monitoring devices market because of their user-friendly design. Also, it effortlessly connects with mobile technologies and enables patients to track their heart activity from anywhere, thus augmenting compliance and engagement. Modern ECG devices will easily integrate with smartphones and tablets, making it easier to monitor heart health for a patient and share the data provided with their healthcare providers; thus, these features support the dominance of ECG devices in the market. At the same time, cardiac telemetry is the fastest-growing segment. The growing FDA clearance for new cardiac telemetry products shows a high demand, which provides tremendous market opportunities.
For instance, in November 2024, SmartCardia SA received FDA clearance for the company's 7-lead live ECG monitoring patch intended for Mobile Outpatient Cardiac Telemetry (OCT/MCT). This waterproof and cable-free patch allows continuous monitoring for up to 14 days. The added feature of remote live ECG monitoring alerts clinicians instantaneously about clinically significant arrhythmias. Cardiac telemetry systems provide continuous real-time monitoring, thus helping patients and allowing early intervention in heart conditions, which is necessary for treating heart conditions. Therefore, this dual trend of developing ECG devices and increased adoption of cardiac telemetry underlines the dynamic evolution of the ambulatory cardiac monitoring market.
North America to Hold Major Market Share
North America has a significant share of the ambulatory cardiac monitoring devices market. The rising heart disease cases are attributed to the market's growth in the region. The Heart Disease and Stroke Statistics: the American Heart Association (AHA) report highlights the alarming statistics. The data estimated that every 34 seconds, someone dies from CVD, and every day in the U.S., 2,552 deaths are reported from CVD. Such facts point to a critical requirement for effective cardiac monitoring solutions. The North American market is increasing due to the availability of treatment solutions on a broad spectrum of distribution channels, the intense presence of key market players, and higher awareness about heart diseases. In September 2024, InfoBionic.Ai, the leading digital health company, launched its ambulatory ECG monitoring system, MoMe.net, in Epic Showroom's Connection Hub. Such innovations, along with the growing incidence of CVD, help to expand the market in this region further and make North America the market leader in the world's ambulatory cardiac monitoring devices market. Additionally, strong reimbursement policies like Medicare spur the growth of the market. The awareness about heart health created by private and governmental organizations increases demand in the market.
Future Market Scenario (2025-2032F)
Ambulatory cardiac monitoring devices hold a very promising future with inventions like minimally invasive techniques and more advanced devices like implantable loop recorders and mobile cardiac telemetry. Favorable reimbursement policies, increased expenditure on health care, and raising awareness of heart health shall make the market highly attractive to manufacturers in this emerging landscape.
In November 2024, Monitra Healthcare Pvt. Ltd. received a U.S. patent for its advanced wireless cardiac monitoring technology. This patch-based system enhances patient compliance and diagnostic accuracy by automatically detecting its orientation and selecting electrode pairs for optimal signal quality, transmitting real-time physiological data wirelessly for analysis. Such innovations create significant market opportunities.
Companies are also upgrading their devices with AI integration that strengthens portfolios and expands the market. In July 2024, Octagos Health, Inc. raised more than USD 43 million to advance AI-driven cardiac device monitoring. Their Atlas AI platform offers continuous monitoring, accurate event detection, EHR integration, and customizable reports that improve decision-making and patient outcomes in cardiology practices.
Key Players Landscape and Outlook
Market players are strengthening their position by acquiring more regulatory approvals and launching new products. These strategies serve to help them expand their market share very effectively. In September 2024, iRhythm Technologies, Inc. received regulatory approval from Japan's PMDA for the Zio 14-day continuous ECG monitoring system. With this approval, iRhythm can obtain reimbursement from the Japanese Ministry of Health, Labour, and Welfare, thereby increasing its market presence and expanding access to its innovative ECG monitoring technology in Japan.
In June 2024, Koninklijke Philips N.V. launched Cardiac Workstation, a new platform for enhancing cardiology patient care and accelerating clinical decision-making in Europe, the Middle East, and Africa. This is a point-of-care and remote analysis of ECG data by advanced algorithms. This innovation further strengthens Philips' market presence, indicating a commitment to advanced healthcare solutions.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.